Other Clinical Trial - OPV as Potential Protection Against COVID-19

Status Active, not recruiting

Clinical Trial Summary

Since the 1960s, studies have shown that oral polio vaccine (OPV) may have beneficial non-specific effects, reducing morbidity and mortality from other infections than polio. Such beneficial non-specific effect have been observed for other live vaccines, including measles, smallpox and BCG vaccine. For BCG, the vaccine for which the mechanism has been studied the most, the effects appear to be mediated through the innate immune system. The COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 has now caused over 7.1 million cases and >400,000 deaths worldwide. As everywhere else, it is anticipated that in Africa the older part of the population will be at risk of severe COVID-19. OPV is widely used in Africa, but for children. Both polio and coronavirus are positive-strand RNA viruses, therefore it is likely that they may induce and be affected by common innate immune mechanisms. In a randomised trial at the Bandim Health Project in Guinea-Bissau, the investigators will assess the effect of providing OPV vs no vaccine to 3400 persons above 50 years of age. The trial will have the power to test the hypothesis that OPV reduces the combined risk of morbidity admission or death (composite outcome) by at least 28% over the subsequent 6 months.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04445428
Study type	Interventional
Source	Bandim Health Project
Contact
Status	Active, not recruiting
Phase	Phase 4
Start date	July 15, 2020
Completion date	May 2022

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04558125` - Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism	Phase 4
Recruiting	`NCT04410510` - P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19	Phase 2/Phase 3
Active, not recruiting	`NCT04420676` - Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection	N/A
Completed	`NCT04419025` - Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease	Phase 2
Completed	`NCT04395911` - Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections	N/A
Completed	`NCT04425317` - Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients	N/A
Withdrawn	`NCT04456426` - Characteristics of Patients With COVID-19 in Meta State, Colombia
Completed	`NCT04526769` - Detecting SARS-CoV-2 in Tears
Suspended	`NCT04385771` - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation	N/A
Completed	`NCT04425720` - Use of Remote Monitoring for COVID-19 Patient	N/A
Completed	`NCT04419610` - RAS and Coagulopathy in COVID19	Early Phase 1
Completed	`NCT04546581` - Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)	Phase 3
Terminated	`NCT04530448` - Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization	Phase 4
Completed	`NCT04435327` - Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
Not yet recruiting	`NCT04524156` - COVID-19 : Transcutaneous pO2 and pCO2 as Predictive Factors for Acute Respiratory Destress Syndrome in Patients Affected With SARS-Cov-2	N/A
Completed	`NCT04441710` - Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus
Completed	`NCT04357834` - WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
Not yet recruiting	`NCT04392427` - New Antiviral Drugs for Treatment of COVID-19	Phase 3
Terminated	`NCT04614025` - Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19	Phase 2
Completed	`NCT04402957` - LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)	Phase 2